Ask AI
ProCE Banner Activity

CE / CME

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs

Video

In this certified on-demand webcast, experts discuss the biology and clinical significance of HER2/ERBB2 alterations in urothelial carcinoma, the role of HER2 testing in guiding treatment, and emerging evidence for HER2-targeted antibody–drug conjugates, including trastuzumab deruxtecan and disitamab vedotin, along with strategies for integrating these therapies and managing associated toxicities in advanced bladder cancer.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 16, 2026

Expiration: September 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, pathologists, and other healthcare professionals who care for patients with bladder cancer.

Program Learning Goal

This activity aims to improve learners' knowledge, confidence, and competence in the optimal management of patients with HER2-positive advanced bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Perform molecular testing and interpretation concordant with expert recommendations to identify patients with advanced bladder cancer who are most likely to benefit from established or emerging HER2-targeted ADCs

  • Evaluate the potential clinical implications of emerging data for novel HER2-targeted ADCs on management of HER2-positive advanced bladder cancer

  • Plan individualized treatment sequences leveraging HER2-targeted ADCs for eligible patients with advanced bladder cancer based on the latest evidence, guidelines, and patient/disease factors

  • Develop strategies to anticipate, monitor, and manage AEs associated with HER2-targeted ADCs in patients with advanced bladder cancer

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shilpa Gupta, MD: consultant/advisor/speaker: Astellas, Bristol Myers Squibb, Johnson & Johnson, Merck, Novartis, Pfizer.

Vadim S. Koshkin, MD: consultant/advisor/speaker: Astellas, Bicycle, Bristol Myers Squibb, Janssen, Loxo Oncology, Merck, Natera, Pfizer, Roche/Genentech; researcher: Astellas, Gilead, Lilly, Pfizer, Taiho, Tyra Oncology.

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Bicycle, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead, Incyte, Infinity, Ipsen, Janssen, Merck, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis, Seattle Genetics, Urogen; researcher: Ada Cap, Agensys, Arvians, Astellas, AstraZeneca, Bayer, BioXcel, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Eisai, Endocyte, Ferring, Genentech, Gilead, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis, Seattle Genetics.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 16, 2026, through September 15, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.